Editas Medicine, Inc. (0IFK.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Editas Medicine, Inc.
Address
11 Hurley Street
Cambridge, MA 02141
United States of America (the)
Phone
617 401 9000
Sector
Healthcare
Industry
Biotechnology
Employees
246
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Gilmore O'Neill | President, Chief Executive Officer & Director | 1.07M | 1964 |
| Amy Parison | Senior Vice President & Chief Financial Officer | 555,520 | 1986 |
| Linda C. Burkly | Executive Vice President & Chief Scientific Officer | 734,972 | 1957 |
| Damien Grierson | Senior Vice President, General Counsel & Corporate Secretary | 0 | N/A |
| Frank Panaccio | Senior Vice President & Chief Business Officer | 0 | N/A |
| Cristi Barnett | Senior Vice President of Corporate Communications & Investor Relations | 0 | N/A |
| Feng Zhang | Co-Founder & Scientific Advisory Board Member | 0 | N/A |
| George McDonald Church | Co-Founder & Scientific Advisory Board Member | 0 | 1954 |
| Tom Love | Vice President of People | 0 | N/A |
| Brieana Buckley | Senior Vice President of Development and Program Leadership | 0 | N/A |
| Gregory Whitehead | Executive Vice President and Chief Technical & Quality Officer | 0 | N/A |
Description
Editas Medicine, Inc. is a clinical-stage company dedicated to developing innovative genomic medicines that address a range of serious diseases. The company utilizes its proprietary gene editing platform, which is founded on CRISPR technology. Its robust pipeline includes EDIT-101, currently undergoing Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a genetic condition causing childhood blindness. Additionally, Editas is developing EDIT-102 for Usher Syndrome 2A, a form of retinitis pigmentosa also linked to hearing loss, and for autosomal dominant retinitis pigmentosa. Another key therapeutic candidate is EDIT-301, aimed at treating sickle cell disease and transfusion-dependent beta-thalassemia. Beyond these programs, the company is advancing gene-edited Natural Killer cell medicines for solid tumors, as well as alpha-beta and gamma delta T cell therapies for various cancers. An early-stage discovery program is also underway for a neurological disease. Editas Medicine maintains strategic collaborations, including a research partnership with Juno Therapeutics, Inc. for engineered T cells in cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover and commercialize gene editing therapies for ocular disorders; and research collaborations with Asklepios BioPharmaceutical, Inc. (AskBio) for a neurological disease treatment. Incorporated in 2013, and formerly known as Gengine, Inc. until its name change in November of that year, Editas Medicine, Inc. is based in Cambridge, Massachusetts.
